Sobi's Revenue Soars with New Treatment Progress

Swedish Orphan Biovitrum AB (Sobi) reported a strong second quarter in 2026 with a 29% rise in total revenue, mainly due to increased sales in their haematology and immunology sectors. They also received promising results from a pivotal study for a new gout treatment, and expect continued revenue growth in the mid-to-high teens. What does it mean for you? If you or someone you know is dealing with rare diseases, Sobi's progress could lead to better treatment options in the future. Plus, if you're into investing, Sobi's impressive growth might be worth checking out.